NuGen Announces Expected Trading Resumption on the TSX Venture Exchange

TORONTO, November 4, 2021 (Newswire.com) - NuGen Medical Devices Inc. (formerly BuzBuz Capital Corp.) (the "Company"), is pleased to announce that following the issuance by the TSX Venture Exchange (the "Exchange") of its final bulletin in respect of the Qualifying Transaction, the common shares of the Company, which were previously halted on August 7, 2020, will commence trading, on a post-consolidation basis, at market open on November 8, 2021, under the trading symbol "NGMD".

The Exchange has previously granted conditional approval in respect of the additional listing of the common shares of the Company resulting from the closing of the Qualifying Transaction which was announced on October 19, 2021.

For further details with respect to the Qualifying Transaction, please see the final non-offering prospectus of the Company dated September 29, 2021, which has been filed under the Company's profile on SEDAR at www.sedar.com.

About NuGen Medical Devices:

NuGen Medical Devices is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies. NuGen Medical Devices principal business is the research, development and commercialization of innovative needle-free injection devices and systems for the administration of subcutaneous medication. It is developing products using needle-free drug delivery technology in several important fields including, but not limited to, anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anaemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, psoriasis as well as DNA and conventional/pediatric vaccines.

Forward-Looking Information

This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Company's common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

For further information, please contact:

Michael Wright President and CEO NuGen Medical Devices Inc. [email protected] (514) 992-9484

Veronique Laberge CFO NuGen Medical Devices Inc. [email protected] (514) 831-8626

Source: nuGen Medical Devices Inc.